CYP3A Polymorphism and Chronic Mercury Intoxication

被引:3
|
作者
Chernyak, Yu. I. [1 ]
Merinova, A. P. [1 ]
机构
[1] East Siberian Inst Med & Ecol Res, Angarsk, Russia
关键词
mercury; chronic mercury intoxication; cytochrome P4503A (CYP3A); genetic polymorphism; antipyrine metabolism; METHYLMERCURY; METABOLISM; GENES;
D O I
10.1007/s10517-020-04738-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
We analyzed the relationship between polymorphic loci of CYP3A genes (CYP3A4 (rs2740574), CYP3A5 (rs776746) and CYP3A7 (rs2257401)) with the development of chronic mercury intoxication. Of 170 men examined, 120 were workers chronically exposed to mercury vapors and 50 were carriers of GG-HSPA1B (+1267A/G) genotype associated with chronic mercury intoxication. Urinary content of 4-hydroxyantipyrine (4-HAP) generated in the reaction predominantly catalyzed by CYP3A4/CYP3A5 was studied in workers without chronic mercury intoxication (group 1, N=46) and patients in the delayed period of chronic mercury intoxication (group 2, N=74) depending on the genotypes of CYP3A4 and CYP3A5. For polymorphic loci CYP3A5 and CYP3A7, a tendency to an increase in the frequency of genotypes with rare alleles was found (p=0.071 and p=0.078) in the combined group (group 2 together with GGHSPA1B genotype carriers) relative to group 1. The high level of linkage disequilibrium was noted, especially for the pair rs776746 and rs2257401 (LD (r)=0.89). In group 2, a trend to 4-HAP decrease compared to group 1 (p=0.056 and p=0.065) was revealed for carriers of AA-CYP3A4 and GG-CYP3A5 genotypes. The involvement of CYP3A in the development of mercury neurotoxic effect remains unclear.
引用
收藏
页码:492 / 495
页数:4
相关论文
共 50 条
  • [1] CYP3A Polymorphism and Chronic Mercury Intoxication
    Yu. I. Chernyak
    A. P. Merinova
    Bulletin of Experimental Biology and Medicine, 2020, 168 : 492 - 495
  • [2] INFLUENCE OF MERCURY AND CADMIUM INTOXICATION ON HEPATIC-MICROSOMAL CYP2E AND CYP3A SUBFAMILIES
    ALEXIDIS, AN
    REKKA, EA
    KOUROUNAKIS, PN
    RESEARCH COMMUNICATIONS IN MOLECULAR PATHOLOGY AND PHARMACOLOGY, 1994, 85 (01) : 67 - 72
  • [3] EFFECT OF CYP3A GENETIC POLYMORPHISM ON THE EFFICACY OF AMLODIPINE IN THE HYPERTENSIVE PATIENTS WITH CHRONIC KIDNEY DISEASES
    Yan, Guangyu
    Dai, Haijiang
    Yuan, Hong
    JOURNAL OF HYPERTENSION, 2018, 36 : E150 - E150
  • [4] Effect of CYP3A gene polymorphism on serum concentration of quetiapine
    Zhang, Y.
    Cui, P.
    Jiang, J.
    Zhu, W.
    Li, Y.
    Liu, F.
    Wu, B.
    Dai, Z.
    Wu, Q.
    EUROPEAN PSYCHIATRY, 2018, 48 : S508 - S508
  • [5] DISSECTING CYP3A INTERACTOME TO UNDERSTAND THE CAUSES OF CYP3A VARIABILITY
    Wang, Danxin
    Lu, Rong
    Rempala, Grzegorza
    Sadee, Wolfgang
    DRUG METABOLISM AND PHARMACOKINETICS, 2018, 33 (01) : S83 - S84
  • [6] CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity
    Green, Henrik
    Skoglund, Karin
    Rommel, Franz
    Mirghani, Rajaa A.
    Lotfi, Kourosh
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (04) : 383 - 386
  • [7] CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity
    Henrik Gréen
    Karin Skoglund
    Franz Rommel
    Rajaa A. Mirghani
    Kourosh Lotfi
    European Journal of Clinical Pharmacology, 2010, 66 : 383 - 386
  • [8] INHIBITORY EFFECTS OF SEVERAL CYP3A INHIBITORS ON CYP3A ACTIVITY IN CATS
    Shah, Syed S.
    Hayashi, Yuhei
    Motoyama, Seiko
    Sasaki, Kazuaki
    Shimoda, Minoru
    DRUG METABOLISM REVIEWS, 2008, 40 : 58 - 58
  • [9] In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease
    Ohnishi, A
    Murakami, S
    Akizuki, S
    Mochizuki, J
    Echizen, H
    Takagi, I
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (11): : 1221 - 1229
  • [10] CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition
    Kharasch, ED
    Thummel, KE
    Watkins, PB
    MOLECULAR INTERVENTIONS, 2005, 5 (03) : 151 - +